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A series of Biginelli adducts bearing different substituents at C-4 position were synthesized by using p-
sulfonic acid calix[4]arene as a catalyst. The in vitro potential to scavenge reactive nitrogen/oxygen spe-
cies (RNS and ROS) and the ability to inhibit cancer cells growth were then investigated. Four adducts
were found to be potent scavengers of 2,2-diphenyl-1-picrylhydrazyl (RNS) and/or superoxide anion
(ROS) radicals. The antiproliferative activity against cancer cells was disclosed for the ﬁrst time for 16
monastrol analogs. The capacity of all compounds to inhibit cancer cells growth was dependent on the
histological origin of cells, except for BA24, which was highly active against all cell lines. BA20 and
BA33were as potent as the reference drug doxorubicin against adriamycin-resistant ovarian and prostate
cancer cells, respectively. These results highlight some monastrol analogs as lead compounds for the
design of new free radical scavengers and anticancer agents.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
A multicomponent reaction (MCR) is deﬁned as the process in
which three ormore reactants are combined in a single step to form
a product that incorporates structural characteristics of each re-
agent. Besides providing structures more complex than the starting
materials, MCRs offer simplicity and efﬁciency to synthetic ap-
proaches.1,2 Despite the spectacular growth of combinatorial chem-
istry in the 80s and 90s, only few MCRs have been developed by
companies (especially pharmaceutical industries) or research labo-
ratories.1–4 The Biginelli reaction, discovered by Pietro Biginelli in
1893, is an MCR that involves the cyclocondensation of acetoacetic
esters, aromatic aldehydes and (thio)urea.5 The products of this
three-component synthesis were identiﬁed as 3,4-dihydropyrimi-
din-2(1H)-ones (DHPMs). Special attention was given to this type
of MCR in the late 20th century with the discovery of the potential
biological activities of compounds bearing a DHPM moiety.6–9 In-
deed, batzeladine B (1) (Fig. 1), a marine natural product isolated
from Batzella sp. was found to inhibit the binding of HIV envelop
protein gp-120 to human CD4 cells.10 Monastrol (BA2) ( Fig. 1)
was identiﬁed as a potent anticancer agent due to its ability to
freely cross cell membrane.11 Such Biginelli adduct affects mitosis
independently of tubulin binding, a mechanism of action presented
by drugs such natural taxanes, vinca alkaloids and epothilones.12–16x: +55 31 3409 5700 (Â.d.F.);
olo), adefatima@qui.ufmg.br
sevier OA license.Other DHPMs, such as SQ 32926 (3) and SQ 32547 (4) (Fig. 1), were
reported to possess antihypertensive properties.17,18 The antioxi-
dant properties of DHPMs were also described by Stefani’s19 and
Kumar’s8 groups. Adducts 5 and 6 (Fig. 1) were able to scavenge
46% of reactive oxygen species (ROS) produced in mice liver, when
used at 100 lM.19 The DHPMs 7 and 8 (Fig. 1) were able to scavenge
2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals by 50% when em-
ployed at 1 mM.8
The diverse biological proﬁle exhibited by Biginelli adducts
brought new perspectives for the development of new drugs based
on DHPM core. Herein, we report the synthesis of twenty-six Bigi-
nelli adducts and their potential as scavengers of reactive nitrogen
and oxygen species (RNS and ROS, respectively) and inhibitors of
cancer cells proliferation.2. Results and discussion
2.1. Synthesis of Biginelli adducts
Twenty-six Biginelli adducts (BA2, BA9-BA33; Table 1) were
synthesized from MCRs that consisted of aldehydes, ethyl acetoac-
etate, (thio)urea and p-sulfonic acid calix[4]arene as a catalyst
according to an approach developed by our group.20 DHPMs
derived from aromatic aldehydes bearing electron-donating or
electron-withdrawing groups were obtained in good yields. Non-
aromatic aldehydes, however, were less reactive, affording moder-
ate yields of Biginelli adducts. Urea furnished better yields when
compared with thiourea (Table 1).
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Figure 1. Biginelli adducts of interesting biological proﬁles.
Table 1
Synthesized Biginelli adducts using p-sulfonic acid calix[4]arene as catalyst
EtO
Me
O
O
XH2N
NH2
+ +
R1
N
H
NH
X
EtO
O
Catalyst (0. 5mol%)a
R1CHO
X = O
X = S
(BA2; BA9-BA33)
EtOH
Reflux (8h)
Product R1 X Yieldb (%)
BA2 3-OH–C6H4 S 52
BA9c C6H5 O 69
BA10 C6H5 S 63
BA11c 4-OH–C6H4 O 81
BA12 4-OH–C6H4 S 77
BA13c 3-OH–C6H4 O 79
BA14c 3,4-OH–C6H3 O 56
BA15 3,4-OH–C6H3 S 49
BA16c 4-OCH3–C6H4 O 89
BA17c 4-OCH3–C6H4 S 78
BA18c 3-OCH3–C6H4 O 78
BA19c 3-OCH3–C6H4 S 74
BA20c 4-OH–3–OCH3–C6H3 O 76
BA21c 4-OH–3–OCH3–C6H3 S 72
BA22 4-OH–3,5–OCH3–C6H2 O 65
BA23 4-OH–3,5–OCH3–C6H2 S 80
BA24c 4-SMe–C6H4 O 92
BA25c 4-SMe–C6H4 S 78
BA26c 3,4-(OCH2O)–C6H3 O 71
BA27c 3,4-(OCH2O)–C6H3 S 64
BA28c 4-F–C6H4 O 91
BA29 4-F–C6H4 S 83
BA30c CH3CH2CH2 O 34
BA31 CH3CH2CH2 S 31
BA32c C6H11 O 38
BA33 C6H11 S 34
a p-Sulfonic acid calix[4]arene.
b Yields of isolated and puriﬁed products.
c Data previously reported by our group20 are listed for comparison.
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Table 2
Concentration of Biginelli adducts necessary to
scavenge DPPH radicals by 50% (SC50)
Biginelli adduct SC50a (lM)
BA14 20.3
BA15 29.7
BA20 105.4
BA21 103.9
BA22 23.3
BA23 24.2
Resveratrol 34.4
a SC50 values were obtained from three
independent experiments performed with
100 lM DPPH, each done in triplicate.
0 2 4 6 8 10
0
2
4
6
8
D
PP
H
 S
ca
ve
ng
in
g 
(nm
ol)
Incubation time (min)
 BA14    BA15    BA22    BA23    Resv
Figure 3. Kinetics of DPPH radical scavenging by Biginelli adducts. The reaction
medium consisted of 10 nmol of DPPH radicals and Biginelli adducts at their SC50 as
it follows: BA14 (20.3 lM), BA15 (29.7 lM), BA22 (23.3 lM), BA23 (24.2 lM) and
resveratrol (Resv, 34.4 lM). Standard deviations were lower than 0.6 nmol. Data are
from three independent experiments, each done in triplicate.
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The 2,2-diphenyl-1-picrylhydrazyl (DPPH) was used as a source
of reactive nitrogen species (RNS). An initial screening was per-
formed with all synthesized compounds to select potential candi-
dates able to capture free radicals. The reaction media consisted
of an ethanolic solution of DPPH at 100 lM and the Biginelli adduct
at 160 lM. Each reaction medium was analyzed at 517 nm after
30 min of incubation under stirring and darkness at 25 C. Resvera-
trol, a known antioxidant derived from plants, was used as a posi-
tive control. The percentage of DPPH radicals scavenged by
(thio)urea-derived Biginelli adducts is shown in Figure 2.
The screening revealed the adducts BA14, BA15, BA22 and BA23
as the best candidates for further studies of DPPH scavenging activ-
ity since such DHPMs were as potent as resveratrol (Fig. 2). Adducts
BA20 and BA21 were also considered promising compounds as
they scavenged 65% of DPPH radicals present in the reaction med-
ium. No signiﬁcant activity was exhibited by other analogs. A phe-
nolic hydroxyl group at para position and oxygenated groups
(hydroxyl or methoxyl) atmeta position in the aromatic ring (Table
1) contributed relevantly to the RNS scavenging activity of BA14,
BA15, BA22 and BA23. The absence of second methoxyl group at
meta position diminished at some degree the adducts potency as
attested by the results obtained for BA20 and BA21. In general,
thiourea-derived Biginelli adducts ( Fig. 2B) seemed to be more
effective than the corresponding oxo-analogs (Fig. 2A) in sequester-
ing DPPH radicals. These results prompted us to further investigate
the concentration of adducts BA14, BA20 and BA22 (oxo-deriva-
tives) and BA15, BA21 and BA23 (thio-derivatives) necessary to
scavenge 50% of DPPH radicals (SC50) present in the reaction med-
ium. A linear behavior of DPPH scavenging was observed when the
DHPMs were used at concentrations up to 40 lM, with exception
of BA20 and BA21 (Fig. S1, Supplementary data). The Biginelli ad-
ducts BA14, BA15, BA22 and BA23 presented SC50 values lower
than that of resveratrol (Table 2). Adducts BA20 and BA21, how-
ever, were about 4-fold less potent than BA14, BA15, BA22 and
BA23. Moreover, these last four adducts were 37- to 40-fold more
potent in scavenging DPPH radicals than the monastrol (BA2) ana-
logs reported elsewhere.8
A kinetic study was then performed with BA14, BA15, BA22 and
BA23 at the corresponding SC50. In the ﬁrst minutes of reaction, the
tested Biginelli adducts were more efﬁcient in scavenging DPPH
radicals than was resveratrol (Fig. 3). The adduct BA14 was twice
as effective as resveratrol after the ﬁrst minute in contact with
DPPH radicals. The capture of DPPH radicals was linear up to the
third minute of reaction for all adducts tested, from which a pla-
teau was reached. In contrast, DPPH scavenging by resveratrol
was almost constant along with 10 min of reaction (Fig. 3), whichBA
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Figure 2. Percentage of reactive nitrogen species scavenged by Biginelli adducts (BA) der
(160 lM) and DPPH radical (100 lM). Resveratrol (Resv) was employed as a positive coresulted in failure to determining the scavenging velocity. The
urea-derivatives BA14 and BA22 were able to scavenge
488.5 ± 14.5 and 527.3 ± 25.7 pmol of DPPH/min, respectively,
while the thiourea-derivatives BA15 and BA23 sequestered
412.8 ± 23.8 and 369.8 ± 6.4 pmol of DPPH/min, respectively
(Fig. 3). Thus, oxo-derived Biginelli adducts were faster than the
corresponding thio-analogs in the scavenging of DPPH radicals.
Combined, these results indicate the great potential of BA14,
BA15, BA22 and BA23 to scavenge RNS.BA
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The ability of Biginelli adducts BA14, BA15, BA22 and BA23 to
scavenge ROS was also investigated. The proﬁle of O2
 scavenging
as a functionof Biginelli adducts concentration ispresented in Figure
4. Resveratrol scavenged O2
 in a concentration-dependent man-
ner. The scavenging of O2
 was linear when Biginelli adducts were
employed at concentrations up to 50 lM, except for BA22. The
BA15was themost potent among the tested compounds, exhibiting
an SC50 value of 25.7 lM. BA14, BA22, BA23 and resveratrol seques-
tered 50% of O2
 radicals when used, respectively, at 33.0, 122.3,Table 3
Concentration of Biginelli adducts (GI50a in lg/mL) that elicits cancer cellsb growth inhibi
Compound U251 NCI-ADR/RES 786-0
BA2 24.0 22.2 4.0
BA9 >250.0 >250.0 >250.0
BA10 26.6 27.4 27.7
BA11 4.2 3.2 25.8
BA12 27.2 83.6 27.5
BA13 5.1 11.7 26.3
BA14 0.25 2.1 25.7
BA15 26.5 24.3 28.3
BA16 11.6 5.7 24.8
BA17 29.0 3.2 25.9
BA18 >250.0 >250.0 >250.0
BA19 28.1 25.6 24.9
BA20 4.5 0.25 17.5
BA21 88.3 59.7 30.0
BA22 >250.0 >250.0 129.2
BA23 0.77 25.0 13.4
BA24 8.0 2.7 2.5
BA25 6.0 35.7 5.3
BA26 34.9 15.5 26.3
BA27 25.9 57.1 27.0
BA28 23.5 3.6 24.7
BA29 28.3 26.1 24.5
BA30 35.4 20.9 18.8
BA31 29.2 40.3 27.7
BA32 141.9 >250.0 >250.0
BA33 25.2 24.1 4.2
Doxorubicinc 0.068 0.14 0.18
a GI50 values were obtained from two independent experiments, each done in triplica
b U251, glioma cells; NCI-ADR/RES, multiple drug-resistant ovarian cancer cells; 786-
cells; OVCAR-03, ovarian cancer cells; HT-29, colon cancer cells.
c Reference drug.
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Figure 4. Percentage of reactive oxygen species scavenged by Biginelli adducts
(BA). The production of O2
 was induced as described in Section 4. Each
compound-test was employed at concentrations that ranged from 12.5 to 200 lM
and the free radical scavenging determined after 10 min of reaction. Standard
deviations were lower than 2%. Data are from three independent experiments, each
done in triplicate.78.0 and 121.4 lM (Fig. 4). Then, the thio-derived Biginelli adducts
were more effective than the corresponding oxo-derivatives.2.4. Antiproliferative activities
Since the disclosure of monastrol (BA2) effect on cancer cells,
only few works explored the potential of BA2 analogs.9,21,22 Based
on this, the effect of a series of synthesized Biginelli adducts (0.25–
250 lg/mL) were investigated on glioma (U251), adriamycin-resis-
tant ovarian cancer (NCI-ADR/RES), kidney cancer (786-0), lung
non-small cancer (NCI-H460), prostate cancer (PC-3), ovarian can-
cer (OVCAR-03) and colon cancer (HT-29) cells. Cell proliferation
was determined by the sulforhodamine B method and doxorubicin
used as a positive control.23 The concentration of Biginelli adducts
that elicited the inhibition of cell growth by 50% (GI50) is summa-
rized in Table 3.
U251, NCI-ADR/RES, PC-3 and OVCAR-03 were the most sensi-
tive cancer cells as attested by the number of Biginelli compounds
that negatively affected cells growth at GI50 6 10 lg/mL (Table 3).
HT-29 cells were the least sensitive to the tested adducts (Table 3).
Adducts BA14 and BA23 were the most active compounds against
U251 cells (GI50 <1 lg/mL). BA11, BA13, BA20, BA24 and BA25
were also promising against U251 cells by exhibiting GI50 around
5 lg/mL (Table 3). BA20 was roughly as potent as doxorubicin
against NCI-ADR/RES cells. Biginelli compounds BA11, BA14,
BA16, BA17, BA24 and BA28 were also effective on NCI-ADR/RES
cells by presenting GI50 between 2 and 6 lg/mL. BA33 was the
most potent adduct against PC-3 cells; its GI50 value was found
to be in the same order of magnitude of that for doxorubicin (Ta-
ble 3). PC-3 cells were also sensitive to BA2, BA17, BA19, BA24,
BA28 and BA29. OVCAR-03 cells were highly sensitive to BA13,
BA14, BA16, BA17, BA19, BA20, BA23-25 and BA33 (Table 3). Com-
pounds BA2, BA24, BA25 and BA33 compromised 786-0 cells
growth by 50% when used at concentrations lower than 6 lg/mLtion by 50%
NCI-H460 PC-3 OVCAR-03 HT29
10.6 5.6 14.4 29.6
28.9 >250.0 >250.0 >250.0
28.0 42.2 27.7 29.8
40.6 135.9 27.3 28.7
>250.0 47.6 37.7 >250.0
42.0 34.7 6.0 27.1
34.0 18.2 1.6 37.8
31.7 25.0 25.0 33.7
>250.0 26.5 8.0 28.3
31.4 5.5 0.99 30.6
>250.0 >250.0 >250.0 >250.0
29.2 10.2 1.3 28.3
125.6 46.3 1.7 28.1
180.4 72.6 11.0 34.9
>250.0 131.7 39.0 >250.0
65.6 19.0 1.9 28.2
3.6 9.5 10.0 10.2
21.6 23.6 8.5 17.2
48.9 83.1 32.4 29.9
27.0 13.4 55.3 31.4
28.1 3.1 27.1 25.3
14.2 1.7 24.7 26.5
49.7 25.0 52.4 17.5
22.5 42.4 38.1 50.4
>250.0 >250.0 >250.0 >250.0
3.5 0.46 2.2 25.2
<0.025 0.24 0.27 0.27
te.
0, renal cancer cells; NCI-H460, non-small lung cancer cells; PC-3, prostate cancer
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and BA33). Only 786-0, NCI-H460 and PC-3 cells were sensitive
to monastrol (BA2), a known anticancer agent, at a concentration
lower than 10 lg/mL. Interestingly, the adduct BA33 was 12-fold
more potent than monastrol against PC-3 cells while BA24 and
BA33 were threefold more potent on NCI-H460 cells (Table 3).
Among the tested compounds, BA24 exhibited a large spectrum
of action affecting all the cell lines at concentrations lower than
10 lg/mL (Table 3). The Biginelli adducts in this study were more
active against cancer cells than those previously reported by
Russowsky et al.21 Overall, the potency of Biginelli adducts was
dependent on the histological origin of cancer cells.
3. Conclusion
The potential to scavenge reactive nitrogen/oxygen species
(RNS and ROS) and the ability to inhibit the growth of cancer cells
were investigated for 26 Biginelli adducts. Among them, BA14,
BA15, BA22 and BA23 were found to be promising RNS and ROS
scavengers, being indeed more potent than the known antioxidant
agent resveratrol. The uncontrolled production of RNS/ROS leads to
cellular damages that may result in a series of diseases.24 Thus,
such adducts may be used as lead compounds for the design of
effective antioxidant agents. Sixteen monastrol-analogs had their
antiproliferative activity against cancer cells evaluated for the ﬁrst
time. The capacity to inhibit cancer cells growth of the Biginelli ad-
ducts was dependent on the histological origin of cells. The adduct
BA24 was the only exception, being active against all cell lines at
concentrations lower than 10 lg/mL. For each cancer cell studied,
at least two adducts were more potent than monastrol (BA2).
Notably, BA20 and BA33 were as potent and the reference drug
doxorubicin against NCI-ADR/RES and PC-3, respectively. These re-
sults disclose some monastrol analogs as lead compounds for
obtaining new anticancer agents.
4. Experimental
4.1. Chemistry
4.1.1. General procedures
All chemicals were obtained from commercially available
sources and used without further puriﬁcation. Anhydrous condi-
tions were not required for the reaction. Melting points (uncor-
rected) were determined on Mettler FP 80 HT apparatus.
Elemental analyses were performed on CHN Perkin-Elmer 2400
apparatus. Infrared spectra were recorded on Perkin Elmer, Spec-
trum One spectrophotometer (ATR). 1H and 13C NMR spectra were
recorded on a Bruker AVANCE DPX-200 spectrometry at 200 MHz
and 50 MHz respectively, in DMSO-d6.
4.1.2. Synthesis of DHPMs
Aldehydes (3 mmol), ethyl acetoacetate (4.5 mmol) and
(thio)urea (4.5 mmol) were dissolved in 3 mL of ethanol containing
p-sulfonic acid calix[4]arene (0.5 mol %). The mixture was heated
under reﬂux and stirred for 8 h.20 All DHPMs were characterized
by NMR (1H and 13C), infrared, melting point and elemental analy-
sis. Characterization data for compounds BA9, BA11-BA14, BA16-
BA21, BA24-BA28, BA30 and BA32 were recently reported by da
Silva et al.20 Data for compounds BA2, BA10, BA15, BA22, BA29,
BA31 and BA33 are listed as Supplementary data.
4.1.2.1. Ethyl 4-(4-hydroxy-3,5-dimethoxyphenyl)-6-methyl-
2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (BA23).
Yield: 80%. Yellow solid. Mp 189–191 C. IR (ATR, cm1): 3473,
3326, 3193, 2945, 2840, 1663, 1619, 1516, 1454, 1432, 1371,1330, 1278, 1217, 1184, 1148, 1119, 859, 821, 789, 753, 672. 1H
NMR (DMSO-d6): d 1.14 (t, 3H, J = 7.0 Hz, CH3), 2.28 (s, 3H, CH3),
3.71 (s, 6H, 2  OCH3), 4.04 (q, 2H, J = 7.0 Hz, CH2), 5.11 (d, 1H,
JH-NH = 3.2, CH), 6.46 (s, 2H, CHAR), 8.42 (s, 1H, OH), 9.58 (s, 1H,
NH), 10.29 (s, 1H, NH); 13C NMR (DMSO-d6): d 14.1 (CH3), 17.1
(CH3), 53.9 (CH), 56.0 (2  OCH3), 59.6 (CH2), 100.9 (C), 103.9
(2  CHAR), 133.7 (CAR), 135.3 (CAR), 144.7 (C), 147.9 (2  CHAR),
165.3 (COO), 174,3 (C(S)). Anal. calcd. for C16H20N2SO5: C, 54.53;
H, 5.72; N, 7.95. Found: C, 54.16; H, 5.63; N, 7.49.
4.2. Biological activities
4.2.1. Scavenging of reactive nitrogen species
The ability of Biginelli adducts BA2 and BA9-BA33 to scavenge
2,2-diphenyl-1-picrylhydrazyl (DPPH) radical, a reactive nitrogen
species (RNS), was determined according to Gülcin,25 with modiﬁ-
cations. The screening of potential candidates was done by incu-
bating each compound-test (160 lM) in an ethanolic medium
containing 100 lM DPPH. The systems were maintained under
stirring and absence of light for 30 min and the absorbance re-
corded at 517 nm. Those compounds with potential scavenging
activity were then tested in the range of 0–160 lM to determine
the concentration necessary to scavenge DPPH radicals by 50%
(SC50). The best compounds were subjected to kinetic studies at
the respective SC50 values. Results presented are from three inde-
pendent experiments, each done in triplicate.
4.2.2. Scavenging of reactive oxygen species
The capacity of Biginelli adducts to scavenge superoxide anions
(O2
) was evaluated in 50 mM phosphate buffer (pH 7.8) contain-
ing 13 mM L-metionine, 75 lM nitroblue tetrazolium, 100 lM
EDTA, 2 lM riboﬂavin and compound-test at 0–200 lM. Reaction
mixtures were incubated for 10 min at 25 C in the presence of
ﬂuorescent light to induce O2
 formation. Controls consisted of
reaction mixtures kept at 25 C for 10 min in absence of light.
The percentage of O2
 scavenged by each compound-test was
determined through spectrophotometric analysis at 575 nm. Re-
sults presented are from three independent experiments, each
done in triplicate.
4.2.3. Antiproliferative assay
Human tumor cell lines U251 (glioma), NCI-ADR/RES (multiple
drugs-resistant ovarian), 786-0 (renal), NCI-H460 (lung, non-small
cells), PC-3 (prostate), OVCAR-03 (ovarian) and HT-29 (colon) were
kindly provided by Frederick Cancer Research & Development Cen-
ter—National Cancer Institute—Frederick, MA, USA. Stock cultures
were grown in RPMI 1640 (GIBCO BRL, Life Technologies) supple-
mented with 5% of fetal bovine serum and penicillin (ﬁnal concen-
tration of 1 mg/mL) and streptomycin (ﬁnal concentration of
200 U/mL).26–28 Cells in 96-well plates (100 lL cells/well) were ex-
posed to Biginelli adducts (0.25–250 lg/mL) for 48 h at 37 C and
5% of CO2. Afterward cells were ﬁxed with 50% trichloroacetic acid,
submitted to sulforhodamine B assay for cell proliferation quanti-
tation at 540 nm.23 The concentration of compound that inhibits
cell growth by 50% (GI50) was determined through non-linear
regression analysis using software ORIGIN 7.5 (OriginLab Corpora-
tion). Doxorubicin was used as a reference drug. Results presented
are from two independent experiments, each done in triplicate.
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